CommercialPrior AuthMedium impact
08.01.40h, Lanreotide (Somatuline® Depot)
Independence Blue Cross·Endocrinology, Oncology, Gastroenterology·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated their medical necessity criteria and medical coding requirements for Lanreotide (Somatuline Depot), a medication used to treat neuroendocrine tumors and acromegaly. The changes affect how this specialty medication must be documented and billed for commercial plan members.
Action Required
By November 17, 2025: Billing team must review updated medical necessity criteria for Lanreotide (Somatuline Depot) claims and ensure proper documentation requirements are met before submitting to Independence Blue Cross commercial plans. Update prior authorization processes and coding procedures according to the new policy requirements to prevent claim denials.